A single tablet contains 0.1 g threonine and 0.005 g of pyridoxine hydrochloride + inactive ingredients (citric acid, povidone and magnesium stearate).
Pharmacodynamics and Pharmacokinetics
After placing the tablet under the tongue, the body absorbs L-threonine and pyridoxine into the blood. Threonine is then broken down into glycine and acetaldehyde (pyridoxine works as a catalyser). Acetic acid and glycine stimulate the synthesis of adenosine triphosphate (ATP) in cells, redox, and cellular respiration.
Administration and dose
Tablets are to be crushed or administered sublingually.
To increase productivity and concentration: take three tablets a day for one week to 10 days. Patients may repeat this course of treatment four times a year.
For treating alcoholism: 1-3 tablets, to be taken three times a day over the course of five days. Patients may repeat the course of treatment ten times a year.
For withdrawal syndrome: 3-4 tablets, to be taken in the first 24 hours. After this, two tablets taken three times a day. The course of treatment should last 10-28 days.
According to the instructions for Biotredin, it is most effective when taken along with glycine.
Doctors may suggest to administer three tablets on an empty stomach to detect and treat latent cravings for alcohol during remission. Acute side effects and facial flushing indicate that alcohol cravings are present. This calls for a course of Biotredin and glycine. Glycine is to be taken 15 minutes before administering 0.1 g of Biotredin under the tongue.
Biotredin is a nootropic medication which improves metabolism and boosts cellular energy. The drug is comprised of L-threonine and pyridoxine hydrochloride (vitamin B6). Together, threonine and vitamin B6 interact to form:
The resulting substance promotes active stimulation of inhibitory processes, oxidation-reduction, and supports respiratory function, and synthesis of adenosine triphosphate in the cells. This medication was developed by Russian researchers at the ‘Biotiki’ pharmaceutical company.
Biotredin gained wide exposure primarily as an effective and safe drug for treating alcohol dependency. Doctors believe the main advantage of Biotredin over other similar drugs is that it is fast acting and can be used to treat children of any age.
The unique combination of threonine and pyridoxine has a synergetic effecton the improvement of the brain function.
Although Biotredin is capable of treating psychological strain and stress, it is not a sedative (it doesn’t suppress the central nervous system). Therefore, it does not cause dependency or lethargy.
L-threonine and vitamin B6 are natural substances for living organisms.
L-threonine is а structural element of the central nervous system and is an essential amino acid the human body cannot synthesize on its own.
L-threonine has the following biological effects on the body:
- Newman et al (1976) Role of L-threonine dehydrogenase in the catabolism of threonine and synthesis of glycine by Escherichia coli https://www.ncbi.nlm.nih.gov/pmc/articles/PMC233149/
- S Bell, J Turner (1976) Bacterial catabolism of threonine. Threonine degradation initiated by L-threonine-NAD+ oxidoreductase https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1163767/
- P Lazarus, L Panasci (1986) Characterization of L-threonine and L-glutamine transport in murine P388 leukemia cells in vitro. Presence of an N-like amino acid transport system https://www.ncbi.nlm.nih.gov/pubmed/3083865
- Growdon et al (1991) L-threonine in the treatment of spasticity https://www.ncbi.nlm.nih.gov/pubmed/1742749
- Davis et al (1994) Dietary threonine imbalance alters threonine dehydrogenase activity in isolated hepatic mitochondria of chicks and rats https://www.ncbi.nlm.nih.gov/pubmed/8089734
- Shimizu et al (1995) Culture conditions for improvement of L-threonine production using a genetically self-cloned L-threonine hyperproducing strain of Escherichia coli K-12 https://www.ncbi.nlm.nih.gov/pubmed/7612996
- Okamoto et al (1997) Hyperproduction of L-threonine by an Escherichia coli mutant with impaired L-threonine uptake https://www.ncbi.nlm.nih.gov/pubmed/9404067
- Simic et al (2001) l-Threonine Export: Use of Peptides To Identify a New Translocator from Corynebacterium glutamicum https://www.ncbi.nlm.nih.gov/pmc/articles/PMC95414/
- E Alasdair (2002) The human L-threonine 3-dehydrogenase gene is an expressed pseudogene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC131051/
- R Machielsen, J van der Oost (2006) Production and characterization of a thermostable L-threonine dehydrogenase from the hyperthermophilic archaeon Pyrococcus furiosus https://www.ncbi.nlm.nih.gov/pubmed/16817900
- Bowyer et al (2009) Structure and function of the l-threonine dehydrogenase (TkTDH) from the hyperthermophilic archaeon Thermococcus kodakaraensis https://www.ncbi.nlm.nih.gov/pubmed/19616102
- Yang et al (2011) Draft Genome Sequence of Escherichia coli XH001, a Producer of l-Threonine in Industry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209229/
- Lee et al (2013) Improved Production of l-Threonine in Escherichia coli by Use of a DNA Scaffold System https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568567/
- Shibata et al (2013) The effects of glycine, L-threonine, and L-cystine supplementation to a 9% casein diet on the conversions of L-tryptophan to nicotinamide and to serotonin in rats https://www.ncbi.nlm.nih.gov/pubmed/24477250